Akebia Ther
$ 0.92
2.79%
12 Jun - close price
- Market Cap 248,005,000 USD
- Current Price $ 0.92
- High / Low $ 0.96 / 0.88
- Stock P/E N/A
- Book Value 0.10
- EPS -0.08
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE -0.79 %
- 52 Week High 4.08
- 52 Week Low 0.82
About
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$4.20
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-26 | 2025-11-10 | 2025-08-07 | 2025-05-08 | 2025-03-13 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-14 | 2023-11-08 | 2023-08-25 |
| Reported EPS | -0.03 | -0.05 | 0.002 | 0.0267 | 0.02 | -0.1 | -0.1 | -0.04 | -0.08 | 0.0032 | -0.08 | -0.06 |
| Estimated EPS | -0.03 | 0.002 | -0.04 | -0.02 | -0.04 | -0.075 | -0.05 | -0.05 | -0.09 | -0.04 | -0.08 | -0.02 |
| Surprise | 0 | -0.052 | 0.042 | 0.0467 | 0.06 | -0.025 | -0.05 | 0.01 | 0.01 | 0.0432 | 0 | -0.04 |
| Surprise Percentage | 0% | -2600% | 105% | 233.5% | 150% | -33.3333% | -100% | 20% | 11.1111% | 108% | 0% | -200% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.03 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AKBA
2026-06-11 00:39:52
The provided article content is just "MSN", which is insufficient to generate a summary or extract any meaningful information about Akebia Therapeutics or its drug Vafseo. It appears the content of the article is missing.
2026-06-11 00:39:49
Akebia Therapeutics announced the strengthening of its Vafseo (vadadustat) patent portfolio with a new patent granted and eligibility for a 5-year extension on a composition of matter patent. This expands Vafseo's intellectual property protective measures, with 14 patents now listed in the Orange Book and expiration dates extending to 2036. The company emphasizes its commitment to making Vafseo a standard of care for dialysis patients, reinforcing its competitive position in the dialysis market.
2026-06-10 08:00:00
Akebia Therapeutics announced that a new patent has been granted and listed in the Orange Book, and a composition of matter patent for Vafseo (vadadustat) is eligible for a 5-year extension. These developments strengthen the company's intellectual property for Vafseo, which now includes 14 Orange Book listed patents with expiration dates extending to 2036. Vafseo, approved in March 2024 for anemia in dialysis patients, has no other oral HIF-PH inhibitors in the U.S. market or development.
2026-06-10 08:00:00
Akebia Therapeutics announced the strengthening of its Vafseo (vadadustat) patent portfolio with a newly granted patent and eligibility for a 5-year extension on a composition of matter patent. This expands their intellectual property with 14 Orange Book-listed patents, extending protection until 2036. The company believes this reinforces its competitive position and commitment to making Vafseo, approved for anemia in CKD patients on dialysis, a standard of care.
2026-06-05 09:39:22
Akebia Therapeutics (AKBA) shares rose 7% due to optimism surrounding its clinical pipeline and projected significant revenue growth for its anemia drug, Vafseo, in 2026. The company plans to start a mid-stage trial for AKB-097 in rare kidney diseases in late 2026 and expects strong Vafseo sales from expanded access and improved adherence rates. Despite a Q4 net loss per share that missed analyst estimates, the company's cash reserves are expected to fund operations for at least two years.
2026-06-05 00:09:56
Akebia Therapeutics (NASDAQ:AKBA) is experiencing increased uptake of its Vafseo treatment for anemia in chronic kidney disease patients, with a 28% rise in prescribing physicians and a 60% increase in patients on therapy. The company anticipates further expansion after the TDAPA period, leading to potentially universal patient access, and highlighted upcoming pipeline milestones including VOCAL data in Q4 and VOICE results in Q1 2027. Akebia also reported two years of cash runway and advancing pipeline programs for rare renal diseases and acute kidney injury.
